Radionuclide Imaging of the Neuroanatomical and Neurochemical Substrate of Cognitive Decline in Parkinson's Disease

Overview

Journal Nucl Med Mol Imaging

Publisher Springer

Date 2024 Jun 27

PMID 38932760

Authors

Samuel Booth

Ji Hyun Ko

Affiliations

Soon will be listed here.

Abstract

Cognitive impairment is a frequent manifestation of Parkinson's disease (PD), resulting in decrease in patients' quality of life and increased societal and economic burden. However, cognitive decline in PD is highly heterogenous and the mechanisms are poorly understood. Radionuclide imaging techniques like positron emission tomography (PET) and single photon emission computed tomography (SPECT) have been used to investigate the neurochemical and neuroanatomical substrate of cognitive decline in PD. These techniques allow the assessment of different neurotransmitter systems, changes in brain glucose metabolism, proteinopathy, and neuroinflammation in vivo in PD patients. Here, we review current radionuclide imaging research on cognitive deficit in PD with a focus on predicting accelerating cognitive decline. This research could assist in the development of prognostic biomarkers for patient stratification and have utility in the development of ameliorative or disease-modifying therapies targeting cognitive deficit in PD.

References

Bartels A, Willemsen A, Doorduin J, de Vries E, Dierckx R, Leenders K . [11C]-PK11195 PET: quantification of neuroinflammation and a monitor of anti-inflammatory treatment in Parkinson's disease?. Parkinsonism Relat Disord. 2009; 16(1):57-9. DOI: 10.1016/j.parkreldis.2009.05.005. View

Shoji Y, Nishio Y, Baba T, Uchiyama M, Yokoi K, Ishioka T . Neural substrates of cognitive subtypes in Parkinson's disease: a 3-year longitudinal study. PLoS One. 2014; 9(10):e110547. PMC: 4203806. DOI: 10.1371/journal.pone.0110547. View

Kouli A, Spindler L, Fryer T, Hong Y, Malpetti M, Aigbirhio F . Neuroinflammation is linked to dementia risk in Parkinson's disease. Brain. 2023; 147(3):923-935. PMC: 10907093. DOI: 10.1093/brain/awad322. View

Belloli S, Morari M, Murtaj V, Valtorta S, Moresco R, Gilardi M . Translation Imaging in Parkinson's Disease: Focus on Neuroinflammation. Front Aging Neurosci. 2020; 12:152. PMC: 7289967. DOI: 10.3389/fnagi.2020.00152. View

Calabresi P, Picconi B, Tozzi A, Ghiglieri V, Di Filippo M . Direct and indirect pathways of basal ganglia: a critical reappraisal. Nat Neurosci. 2014; 17(8):1022-30. DOI: 10.1038/nn.3743. View

Tang C, Eidelberg D . Abnormal metabolic brain networks in Parkinson's disease from blackboard to bedside. Prog Brain Res. 2010; 184:161-76. DOI: 10.1016/S0079-6123(10)84008-7. View

Masliah E, Rockenstein E, Veinbergs I, Sagara Y, Mallory M, Hashimoto M . beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc Natl Acad Sci U S A. 2001; 98(21):12245-50. PMC: 59799. DOI: 10.1073/pnas.211412398. View

Compta Y, Parkkinen L, Kempster P, Selikhova M, Lashley T, Holton J . The significance of α-synuclein, amyloid-β and tau pathologies in Parkinson's disease progression and related dementia. Neurodegener Dis. 2013; 13(2-3):154-6. PMC: 4194631. DOI: 10.1159/000354670. View

Booth S, Park K, Lee C, Ko J . Predicting cognitive decline in Parkinson's disease using FDG-PET-based supervised learning. J Clin Invest. 2022; 132(20). PMC: 9566889. DOI: 10.1172/JCI157074. View

10.

Nobili F, Campus C, Arnaldi D, De Carli F, Cabassi G, Brugnolo A . Cognitive-nigrostriatal relationships in de novo, drug-naïve Parkinson's disease patients: a [I-123]FP-CIT SPECT study. Mov Disord. 2010; 25(1):35-43. DOI: 10.1002/mds.22899. View

11.

Muslimovic D, Post B, Speelman J, Schmand B . Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology. 2005; 65(8):1239-45. DOI: 10.1212/01.wnl.0000180516.69442.95. View

12.

Dupont A, Largeau B, Santiago Ribeiro M, Guilloteau D, Tronel C, Arlicot N . Translocator Protein-18 kDa (TSPO) Positron Emission Tomography (PET) Imaging and Its Clinical Impact in Neurodegenerative Diseases. Int J Mol Sci. 2017; 18(4). PMC: 5412369. DOI: 10.3390/ijms18040785. View

13.

Hilker R, Thomas A, Klein J, Weisenbach S, Kalbe E, Burghaus L . Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology. 2005; 65(11):1716-22. DOI: 10.1212/01.wnl.0000191154.78131.f6. View

14.

Kehagia A, Barker R, Robbins T . Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease. Lancet Neurol. 2010; 9(12):1200-1213. DOI: 10.1016/S1474-4422(10)70212-X. View

15.

Fang C, Lv L, Mao S, Dong H, Liu B . Cognition Deficits in Parkinson's Disease: Mechanisms and Treatment. Parkinsons Dis. 2020; 2020:2076942. PMC: 7128056. DOI: 10.1155/2020/2076942. View

16.

Cash R, Dennis T, LHeureux R, Raisman R, Scatton B . Parkinson's disease and dementia: norepinephrine and dopamine in locus ceruleus. Neurology. 1987; 37(1):42-6. DOI: 10.1212/wnl.37.1.42. View

17.

Firbank M, Yarnall A, Lawson R, Duncan G, Khoo T, Petrides G . Cerebral glucose metabolism and cognition in newly diagnosed Parkinson's disease: ICICLE-PD study. J Neurol Neurosurg Psychiatry. 2017; 88(4):310-316. DOI: 10.1136/jnnp-2016-313918. View

18.

Ekman U, Eriksson J, Forsgren L, Jakobson Mo S, Riklund K, Nyberg L . Functional brain activity and presynaptic dopamine uptake in patients with Parkinson's disease and mild cognitive impairment: a cross-sectional study. Lancet Neurol. 2012; 11(8):679-87. DOI: 10.1016/S1474-4422(12)70138-2. View

19.

Surmeier D, Obeso J, Halliday G . Selective neuronal vulnerability in Parkinson disease. Nat Rev Neurosci. 2017; 18(2):101-113. PMC: 5564322. DOI: 10.1038/nrn.2016.178. View

20.

Kodaka F, Ito H, Kimura Y, Fujie S, Takano H, Fujiwara H . Test-retest reproducibility of dopamine D2/3 receptor binding in human brain measured by PET with [11C]MNPA and [11C]raclopride. Eur J Nucl Med Mol Imaging. 2012; 40(4):574-9. DOI: 10.1007/s00259-012-2312-8. View